Processa Current Deferred Revenue vs Ebit Per Revenue Analysis

PCSA Stock

USD 0.68 0.05 6.85%

Processa Pharmaceuticals financial indicator trend analysis is much more than just breaking down Processa Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Processa Pharmaceuticals is a good investment. Please check the relationship between Processa Pharmaceuticals Current Deferred Revenue and its Ebit Per Revenue accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Processa Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For information on how to trade Processa Stock refer to our How to Trade Processa Stock guide.

Current Deferred Revenue vs Ebit Per Revenue

Current Deferred Revenue vs Ebit Per Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Processa Pharmaceuticals Current Deferred Revenue account and Ebit Per Revenue. At this time, the significance of the direction appears to have strong relationship.

The correlation between Processa Pharmaceuticals' Current Deferred Revenue and Ebit Per Revenue is 0.78. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Ebit Per Revenue in the same time period over historical financial statements of Processa Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Processa Pharmaceuticals' Current Deferred Revenue and Ebit Per Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Processa Pharmaceuticals are associated (or correlated) with its Ebit Per Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebit Per Revenue has no effect on the direction of Current Deferred Revenue i.e., Processa Pharmaceuticals' Current Deferred Revenue and Ebit Per Revenue go up and down completely randomly.

Correlation Coefficient

0.78

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Ebit Per Revenue

Most indicators from Processa Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Processa Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Processa Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For information on how to trade Processa Stock refer to our How to Trade Processa Stock guide.At present, Processa Pharmaceuticals' Selling General Administrative is projected to increase significantly based on the last few years of reporting. Tax Provision is expected to grow at the current pace this year, whereas Issuance Of Capital Stock is forecasted to decline to about 6.8 M.

Processa Pharmaceuticals fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Property Plant And Equipment Net	Non Current Assets Total	Common Stock Shares Outstanding	Other Stockholder Equity	Property Plant And Equipment Gross	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Net Debt	Retained Earnings	Cash	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Current Deferred Revenue	Accounts Payable	Other Current Assets
Total Assets		0.99	-0.02	0.76	0.2	0.42	0.48	-0.57	0.77	-0.21	-0.91	-0.22	0.89	-0.26	0.89	0.54	0.16	0.12	-0.02	0.88	-0.5	0.69	0.43	0.5	0.48	0.38
Total Stockholder Equity	0.99		-0.01	0.71	0.16	0.45	0.49	-0.58	0.79	-0.23	-0.94	-0.26	0.92	-0.25	0.92	0.52	0.1	0.07	-0.09	0.92	-0.53	0.68	0.38	0.48	0.48	0.41
Property Plant And Equipment Net	-0.02	-0.01		0.05	-0.26	0.04	0.15	-0.29	0.13	-0.24	0.06	-0.02	-0.11	0.85	-0.11	0.01	-0.31	-0.24	-0.42	-0.08	-0.21	0.02	-0.1	-0.21	0.03	0.1
Non Current Assets Total	0.76	0.71	0.05		0.39	-0.09	0.24	-0.29	0.32	-0.22	-0.43	0.29	0.41	-0.07	0.41	0.51	0.2	0.52	0.48	0.39	-0.21	0.53	0.6	0.25	0.13	-0.04
Common Stock Shares Outstanding	0.2	0.16	-0.26	0.39		0.09	-0.1	-0.31	-0.1	-0.39	-0.02	-0.03	-0.02	-0.19	-0.02	-0.24	0.59	0.56	0.35	-0.02	-0.38	0.48	0.7	0.25	0.39	0.02
Other Stockholder Equity	0.42	0.45	0.04	-0.09	0.09		0.68	-0.76	0.67	-0.11	-0.59	-0.95	0.54	-0.33	0.54	0.25	0.17	-0.42	-0.67	0.58	-0.6	0.72	-0.07	0.74	0.76	0.64
Property Plant And Equipment Gross	0.48	0.49	0.15	0.24	-0.1	0.68		-0.54	0.66	-0.12	-0.5	-0.65	0.47	-0.39	0.47	0.72	-0.08	-0.12	-0.26	0.51	-0.4	0.75	-0.07	0.65	0.52	0.66
Short Long Term Debt Total	-0.57	-0.58	-0.29	-0.29	-0.31	-0.76	-0.54		-0.71	0.0	0.58	0.7	-0.48	0.02	-0.48	-0.31	-0.37	0.39	0.5	-0.52	0.46	-0.72	-0.33	-0.74	-0.74	-0.54
Other Current Liab	0.77	0.79	0.13	0.32	-0.1	0.67	0.66	-0.71		0.0	-0.87	-0.57	0.84	-0.21	0.84	0.55	0.05	-0.35	-0.41	0.86	-0.43	0.59	0.21	0.59	0.68	0.64
Total Current Liabilities	-0.21	-0.23	-0.24	-0.22	-0.39	-0.11	-0.12	0.0	0.0		0.18	0.02	-0.2	-0.18	-0.2	0.25	0.33	-0.56	0.05	-0.2	0.82	-0.39	-0.05	0.31	-0.16	-0.14
Net Debt	-0.91	-0.94	0.06	-0.43	-0.02	-0.59	-0.5	0.58	-0.87	0.18		0.45	-0.99	0.3	-0.99	-0.43	-0.07	0.14	0.3	-0.99	0.56	-0.59	-0.23	-0.49	-0.58	-0.54
Retained Earnings	-0.22	-0.26	-0.02	0.29	-0.03	-0.95	-0.65	0.7	-0.57	0.02	0.45		-0.39	0.33	-0.39	-0.17	-0.16	0.53	0.71	-0.44	0.48	-0.58	0.16	-0.69	-0.72	-0.67
Cash	0.89	0.92	-0.11	0.41	-0.02	0.54	0.47	-0.48	0.84	-0.2	-0.99	-0.39		-0.33	1.0	0.42	0.02	-0.1	-0.26	1.0	-0.55	0.54	0.19	0.42	0.53	0.5
Non Currrent Assets Other	-0.26	-0.25	0.85	-0.07	-0.19	-0.33	-0.39	0.02	-0.21	-0.18	0.3	0.33	-0.33		-0.33	-0.37	-0.28	-0.16	-0.27	-0.32	0.0	-0.37	-0.06	-0.56	-0.26	-0.25
Cash And Short Term Investments	0.89	0.92	-0.11	0.41	-0.02	0.54	0.47	-0.48	0.84	-0.2	-0.99	-0.39	1.0	-0.33		0.42	0.02	-0.1	-0.26	1.0	-0.55	0.54	0.19	0.42	0.53	0.5
Net Receivables	0.54	0.52	0.01	0.51	-0.24	0.25	0.72	-0.31	0.55	0.25	-0.43	-0.17	0.42	-0.37	0.42		-0.03	-0.01	0.16	0.41	0.05	0.48	-0.02	0.54	0.22	0.13
Common Stock Total Equity	0.16	0.1	-0.31	0.2	0.59	0.17	-0.08	-0.37	0.05	0.33	-0.07	-0.16	0.02	-0.28	0.02	-0.03		0.02	0.25	0.03	0.13	0.24	0.68	0.6	0.5	0.07
Non Current Liabilities Total	0.12	0.07	-0.24	0.52	0.56	-0.42	-0.12	0.39	-0.35	-0.56	0.14	0.53	-0.1	-0.16	-0.1	-0.01	0.02		0.78	-0.13	-0.23	0.2	0.39	-0.27	-0.15	-0.3
Total Liab	-0.02	-0.09	-0.42	0.48	0.35	-0.67	-0.26	0.5	-0.41	0.05	0.3	0.71	-0.26	-0.27	-0.26	0.16	0.25	0.78		-0.3	0.37	-0.12	0.45	-0.17	-0.31	-0.44
Total Current Assets	0.88	0.92	-0.08	0.39	-0.02	0.58	0.51	-0.52	0.86	-0.2	-0.99	-0.44	1.0	-0.32	1.0	0.41	0.03	-0.13	-0.3		-0.56	0.56	0.19	0.45	0.56	0.56
Short Term Debt	-0.5	-0.53	-0.21	-0.21	-0.38	-0.6	-0.4	0.46	-0.43	0.82	0.56	0.48	-0.55	0.0	-0.55	0.05	0.13	-0.23	0.37	-0.56		-0.7	-0.1	-0.15	-0.55	-0.45
Intangible Assets	0.69	0.68	0.02	0.53	0.48	0.72	0.75	-0.72	0.59	-0.39	-0.59	-0.58	0.54	-0.37	0.54	0.48	0.24	0.2	-0.12	0.56	-0.7		0.32	0.72	0.67	0.49
Common Stock	0.43	0.38	-0.1	0.6	0.7	-0.07	-0.07	-0.33	0.21	-0.05	-0.23	0.16	0.19	-0.06	0.19	-0.02	0.68	0.39	0.45	0.19	-0.1	0.32		0.28	0.42	0.19
Current Deferred Revenue	0.5	0.48	-0.21	0.25	0.25	0.74	0.65	-0.74	0.59	0.31	-0.49	-0.69	0.42	-0.56	0.42	0.54	0.6	-0.27	-0.17	0.45	-0.15	0.72	0.28		0.68	0.47
Accounts Payable	0.48	0.48	0.03	0.13	0.39	0.76	0.52	-0.74	0.68	-0.16	-0.58	-0.72	0.53	-0.26	0.53	0.22	0.5	-0.15	-0.31	0.56	-0.55	0.67	0.42	0.68		0.59
Other Current Assets	0.38	0.41	0.1	-0.04	0.02	0.64	0.66	-0.54	0.64	-0.14	-0.54	-0.67	0.5	-0.25	0.5	0.13	0.07	-0.3	-0.44	0.56	-0.45	0.49	0.19	0.47	0.59

Click cells to compare fundamentals

Processa Pharmaceuticals Account Relationship Matchups

Processa Pharmaceuticals fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	25.2M	26.5M	8.6M	5.8M	6.7M	8.3M
Total Stockholder Equity	22.9M	25.5M	7.5M	5.0M	5.7M	6.5M
Property Plant And Equipment Net	159.0K	74.2K	227.6K	148.6K	133.8K	126.4K
Non Current Assets Total	9.0M	8.1M	233.1K	154.1K	177.3K	168.4K
Common Stock Shares Outstanding	375.0K	766.0K	805.5K	1.3M	1.5M	1.0M
Liabilities And Stockholders Equity	25.2M	26.5M	8.6M	5.8M	6.7M	8.3M
Other Stockholder Equity	48.3M	62.3M	71.7M	80.4M	92.4M	97.0M
Property Plant And Equipment Gross	159.0K	103.2K	227.6K	148.6K	170.9K	99.7K
Short Long Term Debt Total	328.1K	78.5K	229.5K	150.6K	135.5K	128.7K
Other Current Liab	695.5K	610.0K	513.2K	335.3K	385.6K	290.6K
Total Current Liabilities	1.2M	971.0K	998.6K	730.6K	840.2K	1.3M
Net Debt	(15.1M)	(16.4M)	(6.3M)	(4.6M)	(4.1M)	(4.3M)
Retained Earnings	(25.4M)	(36.8M)	(64.2M)	(75.4M)	(67.8M)	(64.4M)
Cash	15.4M	16.5M	6.5M	4.7M	5.4M	4.2M
Cash And Short Term Investments	15.4M	16.5M	6.5M	4.7M	5.4M	4.2M
Non Current Liabilities Total	1.1M	7.4K	150.6K	66.9K	60.2K	57.2K
Total Liab	2.3M	978.4K	1.1M	797.5K	717.7K	681.8K
Total Current Assets	16.2M	18.3M	8.4M	5.6M	6.5M	4.8M
Short Term Debt	204.8K	142.2K	157.8K	83.6K	75.3K	71.5K
Intangible Assets	10.4M	9.6M	8.8M	8.1M	9.3M	9.7M
Common Stock	1.4K	1.6K	1.6K	129.0	148.35	140.93
Accounts Payable	320.7K	218.9K	327.5K	311.6K	358.4K	203.8K
Other Current Assets	554.7K	1.8M	3.8M	926.3K	1.1M	727.1K
Net Tangible Assets	(736.8K)	(1.6M)	14.1M	17.4M	20.0M	21.0M
Capital Lease Obligations	165.7K	78.5K	229.5K	150.6K	173.1K	103.8K
Property Plant Equipment	17.4K	228.0K	159.0K	74.2K	85.3K	82.8K
Net Invested Capital	23.1M	25.5M	7.5M	5.0M	5.7M	5.5M
Net Working Capital	15.0M	17.4M	7.4M	4.9M	5.6M	7.3M
Capital Stock	1.4K	1.6K	1.6K	129.0	116.1	110.3

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GM	General Motors
S	SentinelOne

When determining whether Processa Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Processa Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Processa Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Processa Pharmaceuticals Stock:

How To Invest In Processa

Details

Is Processa Stock a good investment?

Details

What is Processa Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Processa Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For information on how to trade Processa Stock refer to our How to Trade Processa Stock guide.

You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Processa Pharmaceuticals. If investors know Processa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Processa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(4.80)

Return On Assets

(1.13)

Return On Equity

(2.12)

The market value of Processa Pharmaceuticals is measured differently than its book value, which is the value of Processa that is recorded on the company's balance sheet. Investors also form their own opinion of Processa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Processa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Processa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Processa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Processa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Processa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Processa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Processa Current Deferred Revenue vs Ebit Per Revenue Analysis

Current Deferred Revenue vs Ebit Per Revenue

Current Deferred Revenue vs Ebit Per Revenue Correlation Analysis

Correlation Coefficient

Current Deferred Revenue

Ebit Per Revenue

Processa Pharmaceuticals fundamental ratios Correlations

Processa Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Processa Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Stockholder Equity	+ 0.99	Total Assets
Cash	+ 0.92	Total Stockholder Equity
Cash And Short Term Investments	+ 0.92	Total Stockholder Equity

Total Current Assets	- 0.99	Net Debt
Cash And Short Term Investments	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Retained Earnings	- 0.95	Other Stockholder Equity
Net Debt	- 0.94	Total Stockholder Equity
Net Debt	- 0.91	Total Assets